```html

Respiratory Distress Syndrome (RDS) in Newborns

Overview

Respiratory Distress Syndrome (RDS), also called hyaline membrane disease, is a condition in which a newborn’s lungs cannot provide enough oxygen to the body because the lung tissue lacks sufficient surfactant. Surfactant is a fatty substance that keeps the tiny air‑sac structures (alveoli) from collapsing during exhalation. Without enough surfactant, the newborn must work much harder to breathe, leading to rapid, shallow respirations and low blood‑oxygen levels.

Who it affects: RDS is most common in premature infants, especially those born before 32 weeks of gestation. It can also occur in full‑term infants who have a genetic surfactant deficiency, maternal diabetes, or a severe infection.

Prevalence: In the United States, RDS affects approximately 1% of all live births but accounts for 10–15% of all NICU (Neonatal Intensive Care Unit) admissions. Globally, the incidence is higher in low‑ and middle‑income countries where premature birth rates are rising (World Health Organization, 2022).

Symptoms

Symptoms usually appear within the first six hours after birth and may worsen over the next 24–48 hours.

• Rapid, shallow breathing (tachypnea) – respiratory rate >60 breaths per minute.
• Grunting sounds – the baby may make a distinctive “grunt” on exhalation as a reflex to keep alveoli open.
• Flaring nostrils – a visible sign of increased effort to draw air.
• Retractions – the skin between the ribs and at the base of the neck pulls in with each breath.
• Chest wall “see‑saw” movement – the chest rises on inhalation but falls quickly on exhalation.
• Blue‑tinged skin (cyanosis) – especially around the lips and fingertips, indicating low oxygen.
• Apnea episodes – brief pauses in breathing that may last several seconds.
• Low blood‑oxygen saturation (SpO₂ < 90%) measured by pulse oximetry.
• Decreased activity or poor feeding due to fatigue from the extra work of breathing.

Causes and Risk Factors

Primary cause

The root cause of RDS is a deficiency of pulmonary surfactant. Surfactant production normally accelerates after 34 weeks of gestation; infants born earlier lack mature type II alveolar cells that secrete this substance.

Risk factors

• Prematurity (< 32 weeks gestation) – risk increases the earlier the birth.
• Maternal diabetes (especially when poorly controlled) – high insulin levels can delay surfactant production.
• Cesarean delivery without labor – labor stimulates catecholamine release that can promote surfactant release.
• Second‑hand smoke exposure during pregnancy.
• Perinatal asphyxia or severe infection (e.g., chorioamnionitis).
• Genetic surfactant protein deficiencies (rare).
• Multiple gestation pregnancies (twins, triplets) – higher likelihood of preterm birth.

Diagnosis

The diagnosis is clinical, supported by imaging and laboratory tests.

Physical examination

Neonatologists assess breathing pattern, chest retractions, heart rate, oxygen saturation, and listen for crackles or “wet” sounds over the lungs.

Chest X‑ray

Typical findings include a “ground‑glass” or “whiteout” appearance with reduced lung volumes, reflecting fluid‑filled alveoli and absent air.

Blood gas analysis

Arterial blood gases often show hypoxemia (low PaO₂) and respiratory acidosis (low pH, high PaCO₂).

Laboratory surfactant testing (research settings)

In specialized centers, amniotic fluid or tracheal aspirate can be tested for surfactant phospholipids, but this is rarely needed for routine care.

Scoring systems

The Silverman‑Anderson Score quantifies the severity of respiratory distress based on five clinical signs (retractions, grunting, nasal flaring, etc.). Scores >3 usually prompt further investigation.

Treatment Options

The main goals are to provide enough oxygen, reduce the work of breathing, and replace or stimulate surfactant production.

Respiratory support

• Continuous Positive Airway Pressure (CPAP) – delivers mild pressure to keep alveoli open; first‑line for most infants with mild‑moderate RDS.
• Mechanical ventilation – invasive ventilation via an endotracheal tube for severe cases where CPAP fails.
• High‑frequency oscillatory ventilation (HFOV) – used when conventional ventilation leads to lung injury.

Surfactant replacement therapy

Administered via endotracheal tube, natural‑derived surfactant (e.g., beractant, poractant alfa) dramatically reduces mortality. Early (< 2 hours after birth) or prophylactic dosing in infants < 30 weeks gestation is recommended by the American Academy of Pediatrics (AAP, 2020).

Medications

• Caffeine citrate – stimulates the respiratory center, reduces apnea, and may shorten ventilation time.
• Antibiotics – given if infection is suspected (e.g., maternal chorioamnionitis).
• Diuretics – used cautiously to manage pulmonary edema in prolonged ventilated infants.

Supportive care

• Thermoregulation – maintain neutral temperature to prevent extra oxygen consumption.
• Fluid management – careful balance to avoid both dehydration and fluid overload.
• Nutrition – early enteral feeds (often breast milk) support growth and lung development.

Living with Respiratory Distress Syndrome (Newborn)

Most infants with RDS improve over the first week as their lungs mature and surfactant therapy takes effect. Parents can help by:

• Monitoring respiratory rate – count breaths for a full minute; >60 may signal worsening distress.
• Observing color changes – any new cyanosis or pallor warrants immediate review.
• Feeding cues – tired infants may fall asleep during feeds; aim for smaller, more frequent meals.
• Skin care – keep the skin clean and dry; pressure injuries can occur from CPAP masks.
• Follow‑up appointments – routine visits with the neonatology team to track growth, oxygen needs, and developmental milestones.

Many babies graduate from supplemental oxygen by 36 weeks post‑menstrual age, but some may need short‑term home oxygen therapy. In these cases, parents receive training on equipment, oxygen saturation monitoring, and emergency protocols.

Prevention

While some risk factors (prematurity) cannot be eliminated, several strategies reduce the incidence and severity of RDS:

• Antenatal corticosteroids – a single course of betamethasone or dexamethasone given to women at risk of preterm delivery (24‑34 weeks) accelerates fetal lung maturation. This intervention lowers RDS rates by 40‑60% (NICHD, 2021).
• Optimal management of maternal diabetes – tight glucose control during pregnancy improves surfactant production.
• Smoking cessation – avoiding tobacco reduces preterm birth risk.
• Preventing preterm labor – progesterone therapy, cervical cerclage, and infection control when indicated.
• Delivery planning – allowing labor to start naturally when feasible, especially for infants >34 weeks, can stimulate surfactant release.

Complications

If RDS is not promptly treated, several serious complications may arise:

• Pulmonary hemorrhage – bleeding into the lungs, more common in extremely premature infants.
• Bronchopulmonary dysplasia (BPD) – chronic lung disease resulting from prolonged ventilation and oxygen toxicity.
• Pneumothorax – air leaks into the chest cavity, causing sudden respiratory collapse.
• Intraventricular hemorrhage (IVH) – bleeding in the brain, linked to fluctuations in blood oxygen.
• Neurodevelopmental delays – infants with severe or prolonged RDS have higher rates of learning and motor difficulties.
• Infection – ventilator‑associated pneumonia or sepsis.

When to Seek Emergency Care

References

• American Academy of Pediatrics. Guidelines for Perinatal Care, 2020.
• National Institute of Child Health and Human Development (NICHD). “Antenatal Corticosteroid Therapy.” 2021.
• Mayo Clinic. “Respiratory distress syndrome in newborns.” Updated 2023.
• World Health Organization. “Newborn health and preterm birth.” 2022.
• Cleveland Clinic. “Hyaline Membrane Disease (Respiratory Distress Syndrome).” 2024.
• J. K. Lee et al., “Surfactant therapy for neonatal RDS: A systematic review,” J Pediatr, 2022.

```